Head-to-head evidence
Parcopa vs Rytary (IPX066)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Parkinson's Disease
Shared mechanism: dopamine precursor · full Parkinson's Disease pipeline
Parcopa
Marketed by UCB
NCT00139867 · Phase 3 · completed
The study used randomization and a conventional carbidopa/levodopa comparator, but it was open-label and focused on treatment preference rather than a hard clinical outcome. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Rytary (IPX066)
Marketed by Amneal Pharmaceuticals
NCT00974974 · Phase 3 · completed
This was a randomized, quadruple-blind, active-controlled phase 3 trial with 393 randomized participants. The primary clinical endpoint—percentage of waking hours spent in the Parkinsonian “off” state—favored IPX066 over immediate-release carbidopa-levodopa and was statistically significant (p<0.0001).
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Parcopa's landscape · Rytary (IPX066)'s landscape